

Serbian Biochemical Society

President: Marija Gavrović-Jankulović

Vice-president: Suzana Jovanović-Šanta

General Secretary: Isidora Protić-Rosić

Treasurer: Milica Popović

Scientific Board

Marija Gavrović-
Jankulović
Svetlana Dinić
Ario de Marco
Suzana Jovanović-
Šanta
Mario Gabričević
Vladimir Mihailović
Theodore G.
Sotiroudis

Natalija Polović
Andreja Rajković
Nataša Simin
Edvard Petri
Sanja Krstić
Željko Popović
Snežana Pantović
Milan Nikolić
Simeon Minić

Organization Committee

Ivan Spasojević
Tanja Ćirković
Veličković
Milica Popović
Aleksandra
Uskoković
Tijana Ćulafić
Isidora Protić-Rosić
Jovana Trbojević-Ivić
Milena Dimitrijević
Srđan Miletić

Proceedings

Editor: Ivan Spasojević

Technical support: Jovana Trbojević-Ivić, Milena Dimitrijević, Tijana Ćulafić

Cover design: Zoran Beloševac

Publisher: Faculty of Chemistry, Serbian Biochemical Society

Printed by: Colorgrafx, Belgrade

No of printed copies: 130

Serbian Biochemical Society
Twelfth Conference

International scientific meeting

September 21-23, 2023, Belgrade, Serbia

“Biochemistry in Biotechnology”

Antitumor potential of novel triphenyltin(IV) complexes with carboxylato *N*-functionalized 2-quinolone ligands

Sanja Jelača^{1*}, Marijana P. Kasalović^{2,3}, Nebojša Đ. Pantelić⁴, Goran N. Kaluđerović², Sanja Mijatović¹, Danijela Maksimović-Ivanić¹

¹*Department of Immunology, Institute for Biological Research "Siniša Stanković" - National Institute of the Republic of Serbia, University of Belgrade, Serbia*

²*Department of Engineering and Natural Sciences, University of Applied Sciences, Merseburg, Germany*

³*Department of Chemistry, Faculty of Science, University of Kragujevac, Serbia*

⁴*Department of Chemistry and Biochemistry, Faculty of Agriculture, University of Belgrade*

**e-mail: sanja.jelaca@ibiss.bg.ac.rs*

Cancer is responsible for millions of deaths worldwide each year and, although great advances have been made in the treatment options, there are still many issues that must be addressed in order to improve cancer therapy. In the present work, anticancer effect of three novel Ph_3SnL complexes ($\text{L1}^-, 3-(4\text{-methyl-2-oxoquinolinyl-1(2H)-yl)propanoato}$; $\text{L2}^-, 2-(4\text{-methyl-2-oxoquinolin-1(2H)-yl)ethanoato}$; $\text{L3}^-, 2-(4\text{-hydroxy-2-oxoquinolin-1(2H)-yl)ethanoato}$), was evaluated against several cancer cell lines (MCA-7, A375, HCT116, 4T1, B16 and CT26). The applied treatment decreased cell viability of all cell lines after 72 h in a dose-dependent manner with IC_{50} values in the low micromolar range. Flow cytometric assessment revealed apoptotic cell death in A375 but not B16 culture, exposed to tested drug. Morphological signs of apoptosis such as shrunk nuclei and condensed chromatin were further confirmed by fluorescent microscopy. Same treatment in B16 lead to cell division block coupled with two-fold increase in the amount of melanin and tyrosinase activity, indicating the differentiation of B16 cells towards melanocytes. In the background of different response of two melanoma cell lines lies dissimilar redox response to the treatment. While in A375 cultures, ROS/RNS production is inhibited in comparison to control, in B16 cells compound $\text{Ph}_3\text{SnL1}$ provokes ROS/RNS generation. Finally, when applied in therapeutic regiment, $\text{Ph}_3\text{SnL1}$ significantly reduced tumor volume in C57BL/6 mice.

Acknowledgements

This study was supported by the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia (Grant Nos. 451-03-47/2023-01/200007 and 451-03-47/2023-01/200116).